Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia
- PMID: 17539693
Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia
Abstract
Cardiovascular disease (CVD), which includes coronary heart, cerebrovascular, and peripheral vascular disease, is the leading cause of death in the United States and most developed countries, accounting for about 50% of all deaths. The major risk factors include obesity and its consequences, dyslipidemia, hypertension, insulin resistance leading to diabetes, and cigarette smoking. In developing countries, CVD will become the leading cause of death due to alarming increases in obesity, sedentary lifestyles, cigarette smoking, and improvements in prevention and treatment of malnutrition and infection. Compared with nonschizophrenics, patients with schizophrenia have a 20% shorter life expectancy (i.e., from 76 to 61 years). In general populations, about 1% die from suicide compared with about 10% among patients with schizophrenia (relative risk = 10). For CVD, the corresponding figures are 50% and about 75% (relative risk = 1.5). In patients with schizophrenia, however, CVD occurs more frequently and accounts for more premature deaths than suicide. Patients with schizophrenia have alarmingly higher rates of obesity, dyslipidemia, hypertension, diabetes, and cigarette smoking than nonschizophrenic individuals in the general population. Compounding these data, patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant. Primary prevention strategies should include the choice of antipsychotic drug regimens that do not adversely affect the major risk factors for CVD.
Similar articles
-
Schizophrenia and increased risks of cardiovascular disease.Am Heart J. 2005 Dec;150(6):1115-21. doi: 10.1016/j.ahj.2005.02.007. Am Heart J. 2005. PMID: 16338246 Review.
-
Cardiovascular risk factors in South America and the Caribbean.Ethn Dis. 1999 Autumn;9(3):468-78. Ethn Dis. 1999. PMID: 10600070
-
Metabolic syndrome and mental illness.Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7. Am J Manag Care. 2007. PMID: 18041878 Review.
-
Cardiovascular disease in Chinese women: an emerging high-risk population and implications for nursing practice.J Cardiovasc Nurs. 2008 Sep-Oct;23(5):386-94; quiz 395-6. doi: 10.1097/01.JCN.0000317446.97951.c2. J Cardiovasc Nurs. 2008. PMID: 18728510
-
Mortality in schizophrenia.Pharmacoepidemiol Drug Saf. 2007 Dec;16(12):1308-12. doi: 10.1002/pds.1496. Pharmacoepidemiol Drug Saf. 2007. PMID: 17944000 Review.
Cited by
-
Psychiatrists' approach to vascular risk assessment in Latin America.World J Psychiatry. 2014 Sep 22;4(3):56-61. doi: 10.5498/wjp.v4.i3.56. World J Psychiatry. 2014. PMID: 25250222 Free PMC article.
-
Prefrontal and Hippocampal Brain Volume Deficits: Role of Low Physical Activity on Brain Plasticity in First-Episode Schizophrenia Patients.J Int Neuropsychol Soc. 2015 Nov;21(10):868-79. doi: 10.1017/S1355617715000983. J Int Neuropsychol Soc. 2015. PMID: 26581798 Free PMC article.
-
Electrocardiographic Evaluation of the Ventricular Arrhythmia Risk in Patients Diagnosed With Schizophrenia.Alpha Psychiatry. 2021 Mar 18;22(2):85-89. doi: 10.5455/apd.7015. eCollection 2021 Mar. Alpha Psychiatry. 2021. PMID: 36425932 Free PMC article.
-
Role of Integrated and Multidisciplinary Approach in Combating Metabolic Syndrome in Patients with Severe Mental Illness.Indian J Psychol Med. 2019 Sep 5;41(5):466-471. doi: 10.4103/IJPSYM.IJPSYM_48_19. eCollection 2019 Sep-Oct. Indian J Psychol Med. 2019. PMID: 31548771 Free PMC article. No abstract available.
-
Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial.Lancet Psychiatry. 2018 Aug;5(8):633-643. doi: 10.1016/S2215-0366(18)30184-6. Epub 2018 Jul 11. Lancet Psychiatry. 2018. PMID: 30001930 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
